GlassScriptPhysician profile
Katlynn White
NPI 1700493673
$3,246.71
in general payments reported to CMS, 2019-2025
33 companies · $824 in 2025
The $824 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $792 · 2022: $677 · 2023: $294 · 2024: $659 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.59 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $338.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $255.03 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Biodelivery Sciences International, INC. | $224.82 | 2021 | |
| Scilex Pharmaceuticals INC. | $215.17 | 2021-2023 | Ztlido |
| Novo Nordisk INC | $193.93 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $182.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Redhill Biopharma INC. | $145.39 | 2021-2022 | |
| Grt US Holding, INC. | $126.94 | 2022 | |
| Tersera Therapeutics LLC | $122.39 | 2022-2023 | Prialt |
| Abbvie INC. | $114.55 | 2023-2025 | |
| Virtus Pharmaceuticals LLC | $88.13 | 2021 | |
| Sumitomo Pharma America, INC. | $77.45 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $75.70 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Corcept Therapeutics | $68.61 | 2024 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.93 | 2023-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $61.15 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $54.41 | 2024-2025 | Repatha, Otezla, Evenity |
| Almatica Pharma LLC | $52.08 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Radius Health, INC. | $49.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $48.87 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.69 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $37.14 | 2022 | |
| Shield Therapeutics INC | $28.08 | 2023 | Accrufer |
| Esperion Therapeutics, INC. | $19.75 | 2023 | Nexletol |
| Bioventus LLC | $19.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.19 | 2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $18.73 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.32 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $17.56 | 2025 | Rexulti |
| Grifols USA, LLC | $15.96 | 2024 | Prolastin-C Liquid |
| Lundbeck LLC | $14.54 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $13.20 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katlynn White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.